Cargando…

Selection bias, investment decisions and treatment effect distributions

When making decisions regarding the investment and design for a Phase 3 programme in the development of a new drug, the results from preceding Phase 2 trials are an important source of information. However, only projects in which the Phase 2 results show promising treatment effects will typically be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiklund, Stig Johan, Burman, Carl‐Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Main Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290610/ https://www.ncbi.nlm.nih.gov/pubmed/34002467 http://dx.doi.org/10.1002/pst.2132

Ejemplares similares

Misspecification of at‐risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation
por: Law, M., et al.
Publicado: (2016)

Equal accuracy for Andrew and Abubakar—detecting and mitigating bias in name-ethnicity classification algorithms
por: Hafner, Lena, et al.
Publicado: (2023)

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014)

Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials
por: Meyer, Elias Laurin, et al.
Publicado: (2022)

A treatment‐specific marginal structural Cox model for the effect of treatment discontinuation
por: Johnson, Dana, et al.
Publicado: (2022)

Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
por: Ristl, Robin, et al.
Publicado: (2020)

Prior distributions for variance parameters in a sparse‐event meta‐analysis of a few small trials
por: Pateras, Konstantinos, et al.
Publicado: (2020)

A comparison of reweighting estimators of average treatment effects in real world populations
por: Lin, Chen‐Yen, et al.
Publicado: (2021)

Estimation of treatment effects in short‐term depression studies. An evaluation based on the ICH E9(R1) estimands framework
por: Mitroiu, Marian, et al.
Publicado: (2022)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

The status of health economic evaluation within decision making in Austria
por: Zechmeister-Koss, Ingrid, et al.
Publicado: (2019)

A novel nonlinear afterload for ex vivo heart evaluation: Porcine experimental results
por: Pigot, Henry, et al.
Publicado: (2022)

Optimal composite scores for longitudinal clinical trials under the linear mixed effects model
por: Ard, M. Colin, et al.
Publicado: (2015)

A cell’s agony of choice: how to cross the Styx?: From morphological to molecular approaches to disclose its decision
por: Bursch, Wilfried
Publicado: (2018)

Assessment of public health interventions for decision support: methods & processes of the evaluation of the Austrian screening programme for pregnant women & children
por: Reinsperger, Inanna, et al.
Publicado: (2019)

The role of hypothermic machine perfusion in selecting renal grafts with advanced histological score
por: Ruberto, Franco, et al.
Publicado: (2022)

STW 5 (Iberogast(®))—a safe and effective standard in the treatment of functional gastrointestinal disorders
por: Ottillinger, Bertram, et al.
Publicado: (2012)

Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study
por: Lasch, Florian, et al.
Publicado: (2021)

A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods
por: Bennett, Maxine, et al.
Publicado: (2021)

A robust permutation test for the concordance correlation coefficient
por: Hutson, Alan D., et al.
Publicado: (2021)

Matrix decomposition in meta‐analysis for extraction of adverse event pattern and patient‐level safety profile
por: Matsuura, Kentaro, et al.
Publicado: (2021)

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing
por: Best, Nicky, et al.
Publicado: (2021)

Practical and robust test for comparing binomial proportions in the randomized phase II setting
por: Attwood, Kristopher, et al.
Publicado: (2021)

Conditional assurance: the answer to the questions that should be asked within drug development
por: Temple, Jane R., et al.
Publicado: (2021)

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
por: Austin, Peter C
Publicado: (2011)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials
por: Bowden, J, et al.
Publicado: (2014)

Do single‐arm trials have a role in drug development plans incorporating randomised trials?
por: Grayling, Michael J., et al.
Publicado: (2015)

Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims
por: Jaki, Thomas, et al.
Publicado: (2016)

Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?
por: Villar, Sofía S., et al.
Publicado: (2017)

A proposal for a new PhD level curriculum on quantitative methods for drug development
por: Jaki, T., et al.
Publicado: (2018)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018)

Α Markov model for longitudinal studies with incomplete dichotomous outcomes
por: Efthimiou, Orestis, et al.
Publicado: (2016)

An optimal stratified Simon two‐stage design
por: Parashar, Deepak, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o96p556l9k5sjkmr86pch5qidt